| Identification | |
| Name: | Lapatinib |
| Synonyms: | GW572016;N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine;Lapatinib base;Lapatinib & its intermediates;Lapatinib(TINIBS);GW 572016;GSK 572016;Lapatinib [INN]; |
| CAS: | 231277-92-2 |
| Molecular Formula: | C29H26ClFN4O4S |
| Molecular Weight: | 581.06 |
| InChI: | InChI=1/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35) |
| Molecular Structure: | ![(C29H26ClFN4O4S) GW572016;N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-...](https://img.guidechem.com/casimg/231277-92-2.gif) |
| Properties | |
| Density: | 1.381 g/cm3 |
| Refractive index: | 1.645 |
| Appearance: | Powder |
| Specification: |
Adverse effects of Lapatinib (CAS NO.231277-92-2): The most common side effects are diarrhea, fatigue, nausea and rashes. Lapatinib is regarded as well tolerated, Like many small molecule tyrosine kinase inhibitors, |
| Safety Data | |
 |
|
